<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03020472</url>
  </required_header>
  <id_info>
    <org_study_id>SU-15086</org_study_id>
    <secondary_id>U19AI057229</secondary_id>
    <nct_id>NCT03020472</nct_id>
  </id_info>
  <brief_title>Kinetics of B-Cell Responses to Live, Attenuated Influenza Vaccine (LAIV) in Young Children Two Years of Age</brief_title>
  <acronym>SLVP016</acronym>
  <official_title>U19 Year 6: Kinetics of B-Cell Responses to Live, Attenuated Influenza Vaccine (LAIV) in Young Children Two Years of Age, SLVP016</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study will investigate B-cell responses following vaccination with live,
      attenuated influenza vaccine (LAIV) in healthy children 2 years of age from blood samples
      taken at designated time points before and after vaccination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an exploratory study to determine the peripheral antibody secreting cell response
      during Days 5-13 after immunization with live, attenuated influenza vaccine (LAIV).

      Investigators hoped to enroll 27 healthy children, 2 years of age who had not had any prior
      LAIV or trivalent inactivated vaccine (TIV) within the past 2 years. Due to low enrollment,
      the study was halted. Due to the limited number of samples, no analysis was performed.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to low enrollment
  </why_stopped>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Received Influenza Vaccine</measure>
    <time_frame>Day 0 to Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Related Adverse Events</measure>
    <time_frame>Day 0 to Day 28</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Post- Immunization B- Cell Response</measure>
    <time_frame>5-13 days post immunization</time_frame>
    <description>Identify peak of the post-immunization B-cell responses following vaccination with live, attenuated influenza vaccine (LAIV)</description>
  </other_outcome>
  <other_outcome>
    <measure>PBMC Samples Will be Tested by Flow Cytometry to Determine the Percentage of Influenza-specific Antibody Cells That Are CD27+CD38+CD19+ Plasmablasts and by ELISPOT.</measure>
    <time_frame>Day 0 to Day 28</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>2008-2009 FluMist LAIV (Intranasal)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2008-2009 FluMist LAIV (Intranasal) Seasonal live, attenuated influenza vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>2008-2009 FluMist LAIV (Intranasal)</intervention_name>
    <description>2008-2009 FluMist vaccine delivered intranasally</description>
    <arm_group_label>2008-2009 FluMist LAIV (Intranasal)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Otherwise healthy children, aged 24-35 months of age, inclusive.

          2. Parent(s) or guardian(s) willing to sign informed consent.

          3. Availability for follow-up for the planned duration of the study.

          4. Acceptable medical history by screening evaluation and brief clinical assessment.

          5. Able to understand and comply with planned study procedures

        Exclusion Criteria

          1. Prior vaccination with LAIV.

          2. TIV vaccination during two prior influenza vaccine seasons

          3. Known prior MD diagnosis of, or hospitalization for influenza

          4. History of asthma, active/recurrent wheezing or reactive airways disease

          5. History of immunodeficiency

          6. Known or suspected impairment of immunologic function including, but not limited to,
             clinically significant liver disease; diabetes mellitus; moderate to severe kidney
             impairment.

          7. Known underlying medical conditions (e.g. hemoglobinopathy, congestive heart failure)
             predisposing to influenza complications.

          8. Household contact with immunodeficiency due to disease, medication or radiation

          9. Child receiving aspirin therapy or aspirin-containing therapy

         10. History of Guillain-Barr√© syndrome

         11. Malignancy, other than squamous cell or basal cell skin cancer

         12. Autoimmune disease

         13. Use of immunosuppressive medication. Corticosteroid nasal sprays are permissible.

         14. Use of antiviral agents against Influenza A and/or B (such as Tamiflu, Relenza,
             Flumodine, Symmetrel) less than 48 hours before and/or less than two weeks after
             administration of FluMist.

         15. History of blood dyscrasias, renal disease, or hemoglobinopathies requiring regular
             medical follow-up or hospitalization during the preceding year.

         16. Use of investigational agents within 30 days prior to study

         17. Receipt of blood products or immunoglobulin in the past 6 months

         18. Donation of the equivalent of a unit of blood within 6 weeks prior to enrollment

         19. Acute febrile illness on the day of vaccination

         20. Known allergies to any component of the vaccine, including eggs or egg products,
             gentamicin, gelatin,or arginine, or known life-threatening reactions to previous
             influenza vaccinations.

         21. Concurrent participation in other investigational protocols or receipt of an
             investigational product within the previous 30 days or planned receipt of an
             investigational product within 28 days following the last immunization dose.

         22. Any condition that, in the opinion of the investigator, might interfere with study
             objectives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Months</minimum_age>
    <maximum_age>35 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cornelia L Dekker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harry B Greenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaosong He, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2017</study_first_submitted>
  <study_first_submitted_qc>January 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2017</study_first_posted>
  <results_first_submitted>January 12, 2017</results_first_submitted>
  <results_first_submitted_qc>January 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 3, 2017</results_first_posted>
  <last_update_submitted>March 17, 2017</last_update_submitted>
  <last_update_submitted_qc>March 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Cornelia L. Dekker</investigator_full_name>
    <investigator_title>Professor, Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Live, attenuated influenza vaccine</keyword>
  <keyword>Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>2008-2009 FluMist LAIV (Intranasal)</title>
          <description>Seasonal live, attenuated influenza vaccine (LAIV)
2008-2009 FluMist LAIV (Intranasal): 2008-2009 FluMist vaccine delivered intranasally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>2008-2009 FluMist LAIV (Intranasal)</title>
          <description>2008-2009 FluMist LAIV (Intranasal) Seasonal live, attenuated influenza vaccine
2008-2009 FluMist LAIV (Intranasal): 2008-2009 FluMist vaccine delivered intranasally</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.4" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Received Influenza Vaccine</title>
        <time_frame>Day 0 to Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2008-2009 FluMist LAIV (Intranasal)</title>
            <description>2008-2009 FluMist LAIV (Intranasal) Seasonal live, attenuated influenza vaccine
2008-2009 FluMist LAIV (Intranasal): 2008-2009 FluMist vaccine delivered intranasally</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Received Influenza Vaccine</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Related Adverse Events</title>
        <time_frame>Day 0 to Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2008-2009 FluMist LAIV (Intranasal)</title>
            <description>2008-2009 FluMist LAIV (Intranasal) Seasonal live, attenuated influenza vaccine
2008-2009 FluMist LAIV (Intranasal): 2008-2009 FluMist vaccine delivered intranasally</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Related Adverse Events</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Post- Immunization B- Cell Response</title>
        <description>Identify peak of the post-immunization B-cell responses following vaccination with live, attenuated influenza vaccine (LAIV)</description>
        <time_frame>5-13 days post immunization</time_frame>
        <population>Due to the low enrollment, the study was terminated and analysis was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>2008-2009 FluMist LAIV (Intranasal)</title>
            <description>2008-2009 FluMist LAIV (Intranasal) Seasonal live, attenuated influenza vaccine
2008-2009 FluMist LAIV (Intranasal): 2008-2009 FluMist vaccine delivered intranasally</description>
          </group>
        </group_list>
        <measure>
          <title>Post- Immunization B- Cell Response</title>
          <description>Identify peak of the post-immunization B-cell responses following vaccination with live, attenuated influenza vaccine (LAIV)</description>
          <population>Due to the low enrollment, the study was terminated and analysis was not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>PBMC Samples Will be Tested by Flow Cytometry to Determine the Percentage of Influenza-specific Antibody Cells That Are CD27+CD38+CD19+ Plasmablasts and by ELISPOT.</title>
        <time_frame>Day 0 to Day 28</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>2008-2009 FluMist LAIV (Intranasal)</title>
          <description>2008-2009 FluMist LAIV (Intranasal) Seasonal live, attenuated influenza vaccine
2008-2009 FluMist LAIV (Intranasal): 2008-2009 FluMist vaccine delivered intranasally</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Cornelia Dekker</name_or_title>
      <organization>Stanford University School of Medicine, Dept. of Pediatrics</organization>
      <phone>650-724-4437</phone>
      <email>cdekker@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

